# US 2024/0189375 A1 · Composition comprising a eukaryotic microalgae or an extract thereof for use in the treatment of a viral disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189375 A1
- Document ID: US20240189375A1
- Status: Published application
- Kind: A1
- Application number: 18/554,492
- Filed: 2022-04-13
- Published: 2024-06-13
- Earliest claimed: 2021-04-13
- Assignees: Philip Morris Products S.A.
- Applicants: Philip Morris Products S.A.
- Inventors: Julia HOENG; Marco VAN DER TOORN; Kasper RENGGLI; Letizia ASTROLOGO
- Web page: https://patentgrep.com/patent/US20240189375A1

## CPC

- A61K 36/05: Chlorophycota or chlorophyta (green algae), e.g. Chlorella
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition is provided, including eukaryotic microalgae or an extract thereof for treatment of a viral disease such as coronavirus, and for use as an inhibitor of the binding of Spike protein receptor binding domain (RBD) to Angiotensin-Converting Enzyme 2 (ACE2). A compound derivable from the eukaryotic microalgae is also provided for treatment of a viral disease. A composition is also provided, including prokaryotic microalgae or an extract thereof for treatment of a viral disease.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

A composition comprising eukaryotic microalgae or an extract thereof for treatment of a viral disease.

### Claim 17 (depends on 16)

The composition according to claim 16, wherein the viral disease is severe acute respiratory syndrome (SARS).

### Claim 18 (depends on 17)

The composition according to claim 17, wherein the viral disease is caused by a SARS-associated virus.

### Claim 19 (depends on 17)

The composition according to claim 17, wherein the viral disease is caused by coronavirus (SARS-COV-2).

### Claim 20 (depends on 16)

The composition according to claim 16, wherein the eukaryotic microalgae is a green eukaryotic microalgae.

### Claim 21 (depends on 16)

The composition according to claim 16, wherein the eukaryotic microalgae is Chlorophyta.

### Claim 22 (depends on 16)

The composition according to claim 16, wherein the eukaryotic microalgae is Chlorella.

### Claim 23 (depends on 16)

The composition according to claim 16, wherein the eukaryotic microalgae is selected from one or more of Chlorella autotrophica, Chlorella colonials, Chlorella lewinii, Chlorella minutissima, Chlorella pituita, Chlorella pulchelloides, Chlorella pyrenoidosa, Chlorella rotunda, Chlorella singularis, Chlorella sorokiniana, Chlorella variabilis, Chlorella volutis, and Chlorella vulgaris.

### Claim 24 (depends on 16)

The composition according to claim 16, wherein the extract comprises one or more of a protein, a lipid, a vitamin, a mineral, folate, iron, a fiber, and/or a pigment.

### Claim 25 (depends on 24)

The composition according to claim 24, wherein the protein is selected from one or more of Plastocyanin (A0A2P6TGD1), Glycine-rich 2 (A0A2P6TDY2), SMAD FHA domain-containing (A0A2P6U3K7), Thylakoid lumenal kDa chloroplastic (A0A2P6TNZ5), Peptidylprolyl isomerase (A0A2P6TGB0), Calmodulin (A0A2P6TFR8), 10 kDa chaperonin-like (A0A2P6THP7), Membrane isoform A (A0A2P6TEF6), L-inducible nipa (A0A2P6TU12), and Beta-Ig-H3 fasciclin (A0A2P6TQQ9).

### Claim 26 (depends on 16)

The composition according to claim 16, wherein the composition is administered locally.

### Claim 27

A compound derivable from eukaryotic microalgae for treatment of a viral disease.

### Claim 28

A composition comprising eukaryotic microalgae or an extract thereof for use as an inhibitor of the binding of the Spike protein receptor binding domain (RBD) to Angiotensin-Converting Enzyme 2 (ACE2).

### Claim 29 (depends on 28)

The composition according to claim 28, without affecting ACE2 activity.

### Claim 30 (depends on 28)

An antiviral agent comprising the composition according to claim 28.

### Claim 31

A composition comprising prokaryotic microalgae or an extract thereof for treatment of a viral disease.